Status:
ACTIVE_NOT_RECRUITING
Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
Lead Sponsor:
ACADIA Pharmaceuticals Inc.
Conditions:
Hyperphagia in Prader-Willi Syndrome
Eligibility:
All Genders
5-30 years
Phase:
PHASE3
Brief Summary
12-week, randomized, double-blind, placebo-controlled, parallel-group study of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome (PWS)
Detailed Description
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study comparing carbetocin nasal spray 3.2 mg TID with placebo (matched placebo nasal spray TID) in subject...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Male or female and 5 through 30 years of age
- Prader-Willi syndrome with a documented disease-causing mutation
- Increased appetite with decreased satiety accompanied by food seeking (consistent with PWS Nutritional Phase 3)
- HQ-CT total score of ≥13 at Screening and Baseline
- CGI-S score for hyperphagia in PWS of ≥4 at Screening and Baseline
- Lives with a caregiver who understands and is willing and able to adhere to study-related procedures and is willing to participate in all study visits
- Exclusion Criteria
- Genetically diagnosed with Schaaf-Yang syndrome or another genetic, hormonal, or chromosomal cognitive impairment besides PWS
- An active upper respiratory infection at the Screening visit or the Baseline visit
- Any clinically significant cardiovascular disorder, renal, hepatic, gastrointestinal, or respiratory disease, including severe asthma
- History of, or current, cerebrovascular disease, brain trauma, epilepsy, or frequent migraines. A history of febrile seizures is not exclusionary
- Nasal surgery within 1 month of Screening visit or planning to have nasal surgery during the study.
- Unwilling to abstain from nasal saline, other nasal irrigation, and other intranasal medications during the Screening period and through the treatment period of the study
- Clinically significant irritability or agitation, requiring initiation of or increase in the dose of antipsychotic medication, within the 6 months prior to the Screening visit
- Used prostaglandins, prostaglandin analogues, or prostaglandin agonists in the 3 months prior to the Baseline visit. Inhibitors of prostaglandin synthesis, such as nonsteroidal anti-inflammatory drugs, are not exclusionary.
- Started a glucagon-like peptide 1 (GLP-1) agonist within the 6 months prior to the Screening visit. Treatment with GLP-1 agonist is allowed if the subject has been taking it for more than 6 months prior to Screening.
- Used oxytocin, desmopressin (DDAVP), tesofensine, diazoxide choline, melanocortin-4 receptor (MC4R) agonists (e.g., setmelanotide), or any medication approved to treat hyperphagia within 6 months prior to the Baseline visit
- Active psychotic symptoms, a history of psychotic symptoms, or a psychotic disorder
- History of suicide attempt or inpatient psychiatric hospitalization
- New food-related interventions, including environment or dietary restrictions, within 1 month prior to the Screening visit or during the Screening period (i.e., before the Baseline visit)
- Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to ensure that all criteria for study participation are met.
Exclusion
Key Trial Info
Start Date :
November 27 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2025
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT06173531
Start Date
November 27 2023
End Date
November 1 2025
Last Update
September 10 2025
Active Locations (30)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's of Alabama
Birmingham, Alabama, United States, 35233
2
Phoenix Children's Hospital
Phoenix, Arizona, United States, 85006
3
University of California Irvine
Orange, California, United States, 92697
4
Stanford University School of Medicine
Palo Alto, California, United States, 94304